General Information of the Compound
Compound ID
CP0041537
Compound Name
5-[6-[(4-methylpiperazin-1-yl)methyl]benzimidazol-1-yl]-3-[(1R)-1-[2-(trifluoromethyl)phenyl]ethoxy]thiophene-2-carboxamide
    Show/Hide
Synonyms
(R)-5-(6-((4-methylpiperazin-1-yl)methyl)-1H-benzo[d]imidazol-1-yl)-3-(1-(2-(trifluoromethyl)phenyl)ethoxy)thiophene-2-carboxamide
5-[6-[(4-Methyl-1-piperazinyl)methyl]-1h-benzimidazol-1-yl]-3-[(1r)-1-[2-(trifluoromethyl)phenyl]ethoxy]-2-thiophenecarboxamide
8QO27TK6Q4
929095-18-1
BCP01720
C27H28F3N5O2S
CHEBI:91333
CHEMBL1908394
CTK8B7590
DTXSID60239197
GSK 461364
GSK 461364A
GSK-461364
GSK-461364A
GSK461364
GSK461364A
GTPL5684
MolPort-016-633-304
SCHEMBL310080
UNII-8QO27TK6Q4
ZHJGWYRLJUCMRT-QGZVFWFLSA-N
    Show/Hide
Structure
Formula
C27H28F3N5O2S
Molecular Weight
543.615
Canonical SMILES
C[C@@H](Oc1cc(sc1C(N)=O)-n1cnc2ccc(CN3CCN(C)CC3)cc12)c1ccccc1C(F)(F)F
    Show/Hide
InChI
InChI=1S/C27H28F3N5O2S/c1-17(19-5-3-4-6-20(19)27(28,29)30)37-23-14-24(38-25(23)26(31)36)35-16-32-21-8-7-18(13-22(21)35)15-34-11-9-33(2)10-12-34/h3-8,13-14,16-17H,9-12,15H2,1-2H3,(H2,31,36)/t17-/m1/s1
    Show/Hide
InChIKey
ZHJGWYRLJUCMRT-QGZVFWFLSA-N
CAS
929095-18-1
Physicochemical Property
logP
5.0921
Rotatable Bonds
7
Heavy Atom Count
38
Polar Areas
76.62
Hydrogen Bond Donor Count
1
Hydrogen Bond Acceptor Count
7
Complexity
38

"RO5" indicates the cutoff set by lipinski's rule of five:

(1) Molecular weight less than 500 Dalton;

(2) xlogp less than 5;

(3) No more than 5 hbonddonor (Hydrogen Bond Donor Count);

(4) No more than 10 hbondacc (Hydrogen Bond Acceptor Count);

(5) No more than 10 rotbonds (Rotatable Bond Count).

    Show/Hide
Click to Show/Hide the External Link(s) of This Compound
PubChem ID
CID: 15983966
SID: 24263067
ChEMBL ID
CHEMBL1908394
Table of Molecular Bioactivities Related to the Compound
Cell Viability or Cytotoxicity Assay
Cell Line ID Cell Line Name Cell Line Organism
CL000714 MM1.S Homo sapiens (Human)  1
1
IC50 = 1 nM
   TI
   LI
   LO
   TS
Clinical Information about the Compound
Drug 1 ( GSK461364 )
Drug Name GSK461364
Company GlaxoSmithKline
Indication
Non-hodgkin lymphoma
Phase 1
Solid tumour/cancer
Phase 1
Target(s)
Polo-like kinase 1 (PLK1)
Inhibitor